Navigation Links
Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
Date:1/27/2011

in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured,
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... York , July 29, 2014 ... Transparency Market Research "Surgical Navigation Systems Market (Neurosurgical Navigation ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... was valued at USD 218.5 million in 2013 and ... from 2014 to 2020, to reach an estimated value ...
(Date:7/29/2014)... LAUDERDALE, Fla. , July 29, 2014 /PRNewswire-iReach/ ... medical service provider, has launched its Medical ... Program.  These services are tailored to the ... excellent standards prompted industry operators to propose that ... MHG Medical,s new program is intended to ...
(Date:7/29/2014)... BEDFORD, Mass. , July 29, 2014  Instrumentation Laboratory ... identity, including a new corporate logo. This is part of ... IL. Founded in Boston, MA ... Group family of companies since 1992.  Other companies in the ... ), Biokit and Systelab ( Barcelona, Spain ).  ...
Breaking Medicine Technology:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
... Bayer HealthCare Pharmaceuticals has become aware of a broad United ... manufactured by the Triad Group and marketed under various brand ... ensure that U.S. patients and physicians using Bayer,s Betaseron are ... recall of the Triad Group alcohol prep products is due ...
... FRANCISCO, Calif., Jan. 7, 2011 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected in ... today announced that the U.S. Food and Drug Administration ... its proprietary PLAC® Test. This PLAC Test product format, ...
Cached Medicine Technology:Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 2Important Information for Betaseron® (interferon beta 1-b) Consumers Regarding Triad Group's Alcohol Prep Products 3diaDexus Announces FDA Clearance for New Automated PLAC Test 2diaDexus Announces FDA Clearance for New Automated PLAC Test 3
(Date:7/29/2014)... 2014 The Natural Multiple Sclerosis Treatment ... story to Gary M. Levin’s cure program. , ... for this serious disorder. Levin says that multiple sclerosis ... can be found in patients. , Dr. Gary ... many years, Levin has worked with patients suffering from ...
(Date:7/29/2014)... Winter is here down under, and ... Sydney’s central business district. That is, until a troop ... the otherwise ordinary day into a celebration—a celebration of ... advocates of The Truth About Drugs, a drug prevention ... They woke up the city with a rousing performance ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... is a 5 step holistic system that will permanently eliminate ... to Thomas Coleman his natural treatment will banish symptoms such ... ringing or beeping sound heard by patients will be gone ... 30 to 60 days. The author of this program says ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) --,The time at which ... their chances for survival, new research suggests. Showing ... or during holidays is associated with a 13 percent ... hours, researchers report. Every year, more than 250,000 ... severe type of heart attack, which is caused by ...
(Date:7/29/2014)... Although the bite of a brown recluse spider is ... an expert notes. It,s still important to recognize ... brown recluse spider bite, warned Dr. Donna Seger, medical ... potentially dangerous bites are on the rise. "As ... The [bite] has classic characteristics, but if physicians are ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... HealthDay Reporter , THURSDAY, Oct. 27 (HealthDay News) ... speech therapy after suffering a massive stroke at the age ... a year-and-a-half completely isolated, unable to communicate, socialize or work ... in Texas, one of a handful of organizations cropping up ...
... , THURSDAY, Oct. 27 (HealthDay News) -- Nipple-sparing ... patients and women who have their breasts removed because ... a new study. For both groups of women, ... feeling reconstructed breast compared to other types of mastectomy, ...
... By Ellin Holohan HealthDay Reporter , ... a lifetime of problems after suffering head injuries from ... new study. From communication deficits to trouble with ... injuries can lead to "substantial long-term reduction" in quality ...
... Whitehead Institute scientists have determined that master transcription factors ... this way, signaling pathways are targeted to genes that ... gene expression to control cell state, growth, differentiation, and ... operate properly, a cell receives instructions from its neighbors ...
... of Nursing (NYUCN) received a two-year, $299,990.00 grant from ... (NCSBN) to research the "Impact of an Internationally Educated ... Nursing Homes." According to the Principal Investigator, Laura ... the NCSBN,s Patient Safety, Practice (LPN/VN, RN), and International ...
... By Maureen Salamon HealthDay Reporter , THURSDAY, Oct. 27 ... its frequent companion, drinking, may be as well, a new study ... week find a link between heavy boozing and a rise in ... hand, studies also suggest that heavier people are less likely to ...
Cached Medicine News:Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 2Health News:Speech Therapy Key to Stroke Rehab, But Many Miss Out 3Health News:Nipple-Sparing Mastectomies May Be Right for Some 2Health News:Children With Head Injuries Can Face Lifetime of Problems 2Health News:Children With Head Injuries Can Face Lifetime of Problems 3Health News:How major signaling pathways are wired to our genome gives new insight into disease processes 2Health News:How major signaling pathways are wired to our genome gives new insight into disease processes 3Health News:Too Much Drinking May Raise Lung Cancer Risk: Study 2Health News:Too Much Drinking May Raise Lung Cancer Risk: Study 3
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
MBP's 200 L large orifice tip is perfect for handling fragile cells, viscous samples and genomic....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: